Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478244 · ClinicalTrials.gov registry record · NA
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00478244 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT00478244, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in the treatment of RDEB.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG busulfan
- PROCEDURE hematopoietic bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478244
The ClinicalTrials.gov registry entry for NCT00478244 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00478244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478244 about?
NCT00478244 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa". RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in ...
What is the current status of trial NCT00478244?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2007-04. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00478244?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), busulfan (DRUG), hematopoietic bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00478244?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.